Hussein A. Tawbi

24.5k total citations · 3 hit papers
152 papers, 4.3k citations indexed

About

Hussein A. Tawbi is a scholar working on Oncology, Molecular Biology and Pulmonary and Respiratory Medicine. According to data from OpenAlex, Hussein A. Tawbi has authored 152 papers receiving a total of 4.3k indexed citations (citations by other indexed papers that have themselves been cited), including 120 papers in Oncology, 67 papers in Molecular Biology and 59 papers in Pulmonary and Respiratory Medicine. Recurrent topics in Hussein A. Tawbi's work include Cancer Immunotherapy and Biomarkers (83 papers), CAR-T cell therapy research (52 papers) and Melanoma and MAPK Pathways (51 papers). Hussein A. Tawbi is often cited by papers focused on Cancer Immunotherapy and Biomarkers (83 papers), CAR-T cell therapy research (52 papers) and Melanoma and MAPK Pathways (51 papers). Hussein A. Tawbi collaborates with scholars based in United States, Australia and Germany. Hussein A. Tawbi's co-authors include John M. Kirkwood, Ahmad A. Tarhini, F. Stephen Hodi, Cindy Sander, Evan J. Lipson, Michael A. Davies, Shreyaskumar Patel, Scott M. Schuetze, Kristen N. Ganjoo and Margaret von Mehren and has published in prestigious journals such as Proceedings of the National Academy of Sciences, Nature Medicine and Journal of Clinical Oncology.

In The Last Decade

Hussein A. Tawbi

143 papers receiving 4.3k citations

Hit Papers

3 papers align trajectories

What are hit papers?

Hit papers significantly outperform the citation benchmark for their cohort. A paper qualifies if it has ≥500 total citations, achieves ≥1.5× the top-1% citation threshold for papers in the same subfield and year (this is the minimum needed to enter the top 1%, not the average within it), or reaches the top citation threshold in at least one of its specific research topics.

Efficacy and Safety of Trabectedin or Dacarbazine for Metastatic Liposarcoma or Leiomyosarcoma After Failure of Conventional Chemotherapy: Results of a Phase III Randomized Multicenter Clinical Trial

2015 576 citations George D. Demetri, Margaret von Mehren et al. Journal of Clinical Oncology profile →
Cardiotoxicity associated with CTLA4 and PD1 blocking immunotherapy

2016 391 citations F. Stephen Hodi, Hussein A. Tawbi et al. Journal for ImmunoTherapy of Cancer profile →
Development of Immunotherapy Combination Strategies in Cancer

2021 231 citations Weiyi Peng, Hussein A. Tawbi et al. Cancer Discovery profile →

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name	h						Papers	Cites
Hussein A. Tawbi United States	32	3.0k	1.4k	1.3k	1.3k	374	152	4.3k
Peter Langmuir United States	30	1.8k 0.6×	1.6k 1.2×	888 0.7×	1.3k 1.0×	118 0.3×	56	4.7k
Julien Adam France	35	3.0k 1.0×	1.6k 1.2×	1.4k 1.1×	1.1k 0.9×	133 0.4×	171	4.7k
Thomas A. Puchalski United States	24	1.5k 0.5×	834 0.6×	789 0.6×	905 0.7×	172 0.5×	51	2.8k
Gregory M. Coté United States	35	1.3k 0.4×	1.4k 1.0×	345 0.3×	1.3k 1.0×	427 1.1×	151	3.4k
Alejandro D. Ricart United States	24	2.5k 0.8×	762 0.6×	780 0.6×	1.4k 1.1×	108 0.3×	57	4.0k
Αthanasios Kotsakis Greece	35	2.5k 0.9×	1.3k 0.9×	717 0.6×	1.0k 0.8×	118 0.3×	166	3.6k
Carlo Lucchesi France	21	1.0k 0.3×	923 0.7×	430 0.3×	1.2k 1.0×	204 0.5×	44	3.1k
Yusri Elsayed United States	22	1.1k 0.4×	606 0.4×	422 0.3×	1.1k 0.8×	196 0.5×	51	2.4k
Biagio Ricciuti United States	33	2.6k 0.9×	1.7k 1.2×	481 0.4×	1.1k 0.8×	76 0.2×	161	3.8k
Stefan Knop Germany	33	2.1k 0.7×	273 0.2×	641 0.5×	1.9k 1.5×	240 0.6×	152	4.4k

Countries citing papers authored by Hussein A. Tawbi

Since Specialization

Citations

This map shows the geographic impact of Hussein A. Tawbi's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Hussein A. Tawbi with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Hussein A. Tawbi more than expected).

Fields of papers citing papers by Hussein A. Tawbi

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Hussein A. Tawbi. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Hussein A. Tawbi. The network helps show where Hussein A. Tawbi may publish in the future.

Co-authorship network of co-authors of Hussein A. Tawbi

This figure shows the co-authorship network connecting the top 25 collaborators of Hussein A. Tawbi. A scholar is included among the top collaborators of Hussein A. Tawbi based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Hussein A. Tawbi. Hussein A. Tawbi is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

Kiany, Simin, Marie‐Andrée Forget, Roland L. Bassett, et al.. (2025). Lymphodepletion, tumor-infiltrating lymphocytes, and high versus low dose IL-2 followed by pembrolizumab in patients with metastatic melanoma. OncoImmunology. 14(1). 2546402–2546402.

Gouda, Mohamed A., Martin H. Voss, Hussein A. Tawbi, et al.. (2025). A phase I/II study of the safety and efficacy of telaglenastat (CB-839) in combination with nivolumab in patients with metastatic melanoma, renal cell carcinoma, and non-small-cell lung cancer. ESMO Open. 10(5). 104536–104536. 17 indexed citations

Levy, Erma, Justin Rains, Elizabeth Sirmans, et al.. (2024). The DIET study: A randomized controlled trial of a high fiber diet intervention (HFDI) in patients (pts) with melanoma receiving immune checkpoint blockade (ICB).. Journal of Clinical Oncology. 42(16_suppl). 9558–9558. 2 indexed citations

Amaria, Rodabe N., Jennifer L. McQuade, Michael A. Davies, et al.. (2024). OBX-115, an interleukin 2 (IL2)-sparing engineered tumor-infiltrating lymphocyte (TIL) cell therapy, in patients (pts) with immune checkpoint inhibitor (ICI)-resistant unresectable or metastatic melanoma.. Journal of Clinical Oncology. 42(16_suppl). 9515–9515. 17 indexed citations

Menzies, Alexander M., Georgina V. Long, Hussein A. Tawbi, et al.. (2024). POLARIS: A phase 2 trial of encorafenib plus binimetinib evaluating high-dose and standard-dose regimens in patients with BRAF V600-mutant melanoma with brain metastasis. Neuro-Oncology Advances. 6(1). vdae033–vdae033. 1 indexed citations

Dummer, Reinhard, Mitchell P. Levesque, Elisa Bellini, et al.. (2024). Atezolizumab (A), cobimetinib (C), and vemurafenib (V) in patients (pts) with BRAF^V600 mutation–positive melanoma with central nervous system (CNS) metastases (mets): Final results and exploratory biomarker analysis from the phase 2 TRICOTEL study.. Journal of Clinical Oncology. 42(16_suppl). 9550–9550.

López-Olivo, María A., Gabrielle F. Duhon, Mehmet Altan, et al.. (2023). Physician Views on the Provision of Information on Immune Checkpoint Inhibitor Therapy to Patients with Cancer and Pre-Existing Autoimmune Disease: A Qualitative Study. Cancers. 15(10). 2690–2690. 4 indexed citations

Tawbi, Hussein A., F. Stephen Hodi, Evan J. Lipson, et al.. (2023). Nivolumab (NIVO) plus relatlimab (RELA) vs NIVO in previously untreated metastatic or unresectable melanoma: 2-year results from RELATIVITY-047.. Journal of Clinical Oncology. 41(16_suppl). 9502–9502. 7 indexed citations

Tawbi, Hussein A., Ryan J. Sullivan, David Feltquate, et al.. (2023). Society for Immunotherapy of Cancer (SITC) checkpoint inhibitor resistance definitions: efforts to harmonize terminology and accelerate immuno-oncology drug development. Journal for ImmunoTherapy of Cancer. 11(7). e007309–e007309. 7 indexed citations

10.

Kirkwood, John M., Lisa A. Kottschade, Robert R. McWilliams, et al.. (2023). Real-World Outcomes with Immuno-Oncology Therapies in Advanced Melanoma: Final Results of the OPTIMIzE Registry Study. Immunotherapy. 16(1). 29–42. 3 indexed citations

11.

Morad, Golnaz, Sheila Duncan, Sherise D. Ferguson, et al.. (2023). Longitudinal single-cell (sc) immune profiling of cerebrospinal fluid (CSF) from melanoma patients (pts) with leptomeningeal disease (LMD) treated with intrathecal (IT) and intravenous (IV) nivolumab (N).. Journal of Clinical Oncology. 41(16_suppl). 2015–2015.

12.

Schadendorf, Dirk, Hussein A. Tawbi, Evan J. Lipson, et al.. (2023). Health-related quality of life with nivolumab plus relatlimab versus nivolumab monotherapy in patients with previously untreated unresectable or metastatic melanoma: RELATIVITY-047 trial. European Journal of Cancer. 187. 164–173. 9 indexed citations

13.

Wilmott, James S., Hussein A. Tawbi, Johnathan A. Engh, et al.. (2022). Clinical Features Associated with Outcomes and Biomarker Analysis of Dabrafenib plus Trametinib Treatment in Patients with BRAF-Mutant Melanoma Brain Metastases. Clinical Cancer Research. 29(3). 521–531. 9 indexed citations

14.

Schadendorf, Dirk, Caroline Robert, Reinhard Dummer, et al.. (2021). Pyrexia in patients treated with dabrafenib plus trametinib across clinical trials in BRAF-mutant cancers. European Journal of Cancer. 153. 234–241. 16 indexed citations

15.

Hampel, Paul J., Timothy G. Call, Wei Ding, et al.. (2020). Incidental Richter transformation in chronic lymphocytic leukemia patients during temporary interruption of ibrutinib. Blood Advances. 4(18). 4508–4511. 13 indexed citations

16.

Lucci, Anthony, Carolyn Hall, Sapna P. Patel, et al.. (2020). Circulating Tumor Cells and Early Relapse in Node-positive Melanoma. Clinical Cancer Research. 26(8). 1886–1895. 52 indexed citations

17.

Peng, Weiyi, Leila J. Williams, Chunyu Xu, et al.. (2019). Anti-OX40 Antibody Directly Enhances The Function of Tumor-Reactive CD8+ T Cells and Synergizes with PI3Kβ Inhibition in PTEN Loss Melanoma. Clinical Cancer Research. 25(21). 6406–6416. 33 indexed citations

18.

Demetri, George D., Margaret von Mehren, Robin L. Jones, et al.. (2015). Efficacy and Safety of Trabectedin or Dacarbazine for Metastatic Liposarcoma or Leiomyosarcoma After Failure of Conventional Chemotherapy: Results of a Phase III Randomized Multicenter Clinical Trial. Journal of Clinical Oncology. 34(8). 786–793. 576 indexed citations breakdown →

19.

Paraiso, Kim H.T., Meghna Das Thakur, Bin Fang, et al.. (2014). Ligand-Independent EPHA2 Signaling Drives the Adoption of a Targeted Therapy–Mediated Metastatic Melanoma Phenotype. Cancer Discovery. 5(3). 264–273. 85 indexed citations

20.

Fourcade, Julien, Zhaojun Sun, Ornella Pagliano, et al.. (2013). PD-1 and Tim-3 Regulate the Expansion of Tumor Antigen–Specific CD8+ T Cells Induced by Melanoma Vaccines. Cancer Research. 74(4). 1045–1055. 175 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact